CSS
AEON icon

Cubist Systematic Strategies’s AEON Biopharma AEON Stock Holding History

Cubist Systematic Strategies’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,669
Closed -$1.93M – 3851
2022
Q4 		$1.93M Sell
2,669
-487
-15% -$349K 0.01% 1889
2022
Q3 		$2.24M Buy
3,156
+535
+20% +$379K 0.01% 1887
2022
Q2 		$1.85M Buy
2,621
+2,038
+350% +$1.44M 0.01% 1936
2022
Q1 		$410K Buy
583
+251
+76% +$176K ﹤0.01% 2658
2021
Q4 		$232K Buy
+332
New +$233K ﹤0.01% 2950

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Cubist Systematic Strategies's AEON Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 2,669 shares — an estimated $1.93M sold.

Cubist Systematic Strategies first reported a position in AEON in Q4 2021 and held it in 5 quarters. The position peaked at $2.24M in Q3 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 2,669 AEON Biopharma shares in Q1 2023, an estimated $1.93M.
  • Cubist Systematic Strategies first reported a position in AEON Biopharma in Q4 2021 and held it in 5 quarters.
  • Cubist Systematic Strategies's AEON Biopharma position peaked at $2.24M in Q3 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.